ELC-301

N/A

Report date: 2023/08/24 20:01:02

Base Information

Drug NameELC-301

Drug Alias NameCAR20(NAP)-T Therapy(Uppsala University)CAR20(NAP)-T(Uppsala University)Autologous CAR-T cells targeting CD20(Uppsala University)ELC301ELC-301

ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionImmunologic cytotoxicityT lymphocyte replacementsB-lymphocyte antigen CD20 modulators

TargetsB-lymphocyte antigen CD20

Therapy Area/IndicationsLymphoma, B-CellLymphoma, Non-Hodgkin

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySweden

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesElicera Therapeutics AB Uppsala University

China Registration ClassN/A

Develop Information

Active CompaniesUppsala University Hospital Uppsala University Elicera Therapeutics AB

Inactive CompaniesN/A

Active IndicationsLymphoma, B-CellLymphoma, Non-Hodgkin

Inactive IndicationsN/A

Other Information

ATC CodeN/A